SCHEDULE: Deep Track Capital Amends RAPT Therapeutics Stake

Deep Track Capital and affiliates report a 0.40% beneficial ownership in RAPT Therapeutics, Inc. common stock as of December 31, 2025.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 110,448 shares of RAPT Therapeutics, Inc. common stock.
• This ownership represents 0.40% of RAPT Therapeutics' outstanding common stock.
• The calculation is based on 27,710,871 common shares outstanding as of November 3, 2025, as reported in the issuer's Form 10-Q.
• The reporting persons share both voting and dispositive power over all 110,448 shares.
• The filing is an Amendment No. 1 to a previously filed Schedule 13G.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard regulatory disclosure of passive ownership and does not provide operational or financial insights into RAPT Therapeutics.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding RAPT Therapeutics' future performance or operations.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser, certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures of passive institutional ownership. This amendment indicates a change in Deep Track Capital's stake in RAPT Therapeutics, though the current reported percentage of 0.40% is below the typical 5% threshold for initial 13G filings, suggesting a reduction from a prior higher stake or a routine annual update for a previously established position.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership stake of a significant institutional investor, Deep Track Capital, and its affiliates.

Key Dates

Keywords

RAPT Therapeutics, Deep Track Capital, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology